今日（9月28日）晚间，南京医药披露，公司与广州白云山医药集团股份有限公司（以下简称“白云山”）及广州广药股权投资合伙企业（有限合伙）（以下简称“广药二期基金”）签署《战略投资协议》。具体来看，白云山下属广药二期基金，拟通过协议方式投资受让南京医药现第二大股东AHAPL所全部持有的公司11.04%股权。交易各方确定的股份转让价款为5.18元/股，转让总额约为7.48亿元。目前，南京医药股票价格为...
Source Link今日（9月28日）晚间，南京医药披露，公司与广州白云山医药集团股份有限公司（以下简称“白云山”）及广州广药股权投资合伙企业（有限合伙）（以下简称“广药二期基金”）签署《战略投资协议》。具体来看，白云山下属广药二期基金，拟通过协议方式投资受让南京医药现第二大股东AHAPL所全部持有的公司11.04%股权。交易各方确定的股份转让价款为5.18元/股，转让总额约为7.48亿元。目前，南京医药股票价格为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.